NYU Doctors Explain DCIS

Larotrectinib led to rapid/durable responses and high disease control rates in children with TRK fusion-position central nervous system cancers.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Most patients with triple-negative breast cancer experienced a protocol-defined immune response with an investigational vaccine, phase 1 data showed.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

PARP inhibitors have changed the way we think about [managing] ovarian cancer,” Whitney Goldsberry, MD, said

The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.